Raymond James & Associates Sangamo Therapeutics, Inc Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Raymond James & Associates holds 13,950 shares of SGMO stock, worth $5,022. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,950Holding current value
$5,022% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding SGMO
# of Institutions
138Shares Held
100MCall Options Held
35.5KPut Options Held
65.8K-
Wasatch Advisors Inc Salt Lake City, UT20.1MShares$7.25 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY17MShares$6.11 Million0.15% of portfolio
-
Black Rock Inc. New York, NY13.3MShares$4.78 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$4.39 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.94MShares$1.78 Million0.01% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $56.4M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...